Pharmacogenetics of warfarin: Challenges and opportunities

Journal of Human Genetics

Volumn 58, Issue 6, 2013, Pages 334-338

  Lee, Ming Ta Michael ^a,b,c   Klein, Teri E ^d  

^a Institute of Physical and Chemical Research   (Japan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; CYP4F2; pharmacogenetics; VKORC1; warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; OXIDOREDUCTASE; PROTHROMBIN; WARFARIN;

ALGORITHM; ANTICOAGULATION; BLOOD CLOTTING TIME; DRUG SAFETY; GENOTYPE; HEREDITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; PROTHROMBIN TIME; REVIEW;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84880897371     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2013.40     Document Type: Review

References (99)

1. Hirsh, J. Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. Am. Heart J. 123, 1115-1122 (1992).
2. Hirsh, J., Dalen, J., Anderson, D. R., Poller, L., Bussey, H., Ansell, J. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, 8S-21S (2001). (Pubitemid 32154192)
3. Laupacis, A., Albers, G., Dalen, J., Dunn, M., Feinberg, W. & Jacobson, A. Antithrombotic therapy in atrial fibrillation. Chest 108, 352S-359S (1995).
4. Stein, P. D., Alpert, J. S., Copeland, J., Dalen, J. E., Goldman, S. & Turpie, A. G. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 108, 371S-379S (1995).
5. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). (e-pub ahead of print 7 December 2011; http://www.fda.gov/drugs/ drugsafety/ucm282724.htm).
6. Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
7. Wittkowsky, A. K. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin. Vasc. Med. 3, 221-230 (2003). (Pubitemid 37280710)
8. Bell, R. G. & Matschiner, J. T. Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature 237, 32-33 (1972).
9. Wallin, R. & Martin, L. F. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J. Clin. Invest. 76, 1879-1884 (1985). (Pubitemid 16196058)
10. Loebstein, R., Yonath, H., Peleg, D., Almog, S., Rotenberg, M., Lubetsky, A. et al. Interindividual variability in sensitivity to warfarin-nature or nurture? Clin. Pharmacol. Ther. 70, 159-164 (2001).
11. Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T. et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263 (2003). (Pubitemid 36269676)
12. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
13. van den Besselaar, A. M., Poller, L. & Tripodi, A. Definition of the International Normalized Ratio (INR) and its consequences for the calibration procedure of thromboplastin preparations: a rebuttal. J. Thromb. Haemost. 2, 1490-1491, reply 1492-1494 (2004).
14. Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C. et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br. J. Haematol. 154, 311-324 (2011).
15. Bogousslavsky, J. & Regli, F. Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke. Acta Neurol. Scand. 71, 464-471 (1985).
16. Gullov, A. L., Koefoed, B. G. & Petersen, P. Bleeding complications to long-term oral anticoagulant therapy. J. Thromb. Thrombolysis 1, 17-25 (1994).
17. Landefeld, C. S. & Beyth, R. J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95, 315-328 (1993). (Pubitemid 23270290)
18. Budnitz, D. S., Lovegrove, M. C., Shehab, N. & Richards, C. L. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365, 2002-2012 (2011).
19. Hirsh, J., Fuster, V., Ansell, J. & Halperin, J. L. American Heart Association/American College of Cardiology F. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 41, 1633-1652 (2003).
20. Lin, L. J., Cheng, M. H., Lee, C. H., Wung, D. C., Cheng, C. L. & Kao Yang, Y. H. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in Taiwan. Clin. Ther. 30, 1726-1736 (2008).
21. Rasmussen, M. A., Skov, J., Bladbjerg, E. M., Sidelmann, J. J., Vamosi, M. & Jespersen, J. Multivariate analysis of the relation between diet and warfarin dose. Eur. J. Clin. Pharmacol. 68, 321-328 (2012).
22. Important information to know when you are taking: warfarin (coumadin) and vitamin k. (e-pub ahead of print 5 September 2012; http://www.cc.nih.gov/ ccc/patient-education/drug-nutrient/coumadin1.pdf).
23. Weathermon, R. & Crabb, D. W. Alcohol and medication interactions. Alcohol Res. Health 23, 40-54 (1999).
24. Heimark, L. D., Wienkers, L., Kunze, K., Gibaldi, M., Eddy, A. C., Trager, W. F. et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51, 398-407 (1992).
25. Juurlink, D. N. Drug interactions with warfarin: what clinicians need to know. CMAJ 177, 369-371 (2007). (Pubitemid 47339534)
26. Suh, D. C., Nelson, W. W., Choi, J. C. & Choi, I. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation. Clin. Ther. 34, 1569-1582 (2012).
27. Thijssen, H. H., Soute, B. A., Vervoort, L. M. & Claessens, J. G. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb. Haemost. 92, 797-802 (2004). (Pubitemid 39386707)
28. Limdi, N. A., Limdi, M. A., Cavallari, L., Anderson, A. M., Crowley, M. R., Baird, M. F. et al. Warfarin dosing in patients with impaired kidney function. Am. J. Kidney Dis 56, 823-831 (2010).
29. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T. et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
30. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J. et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392 (1995). (Pubitemid 26010117)
31. Takahashi, H. & Echizen, H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 3, 202-214 (2003). (Pubitemid 37167925)
32. Bhasker, C. R., Miners, J. O., Coulter, S. & Birkett, D. J. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7, 51-58 (1997). (Pubitemid 27153319)
33. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996). (Pubitemid 26288624)
34. Aithal, G. P., Day, C. P., Kesteven, P. J. & Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999). (Pubitemid 29103806)
35. Lindh, J. D., Holm, L., Andersson, M. L. & Rane, A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
36. Scott, S. A., Jaremko, M., Lubitz, S. A., Kornreich, R., Halperin, J. L. & Desnick, R. J. CYP2C98 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10, 1243-1255 (2009).
37. Limdi, N., Goldstein, J., Blaisdell, J., Beasley, T., Rivers, C. & Acton, R. Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Personalized Med. 4, 157-169 (2007). (Pubitemid 46845895)
38. Cavallari, L. H., Langaee, T. Y., Momary, K. M., Shapiro, N. L., Nutescu, E. A., Coty, W. A. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464 (2010).
39. Kaminsky, L. S. & Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997). (Pubitemid 26425815)
40. Wadelius, M., Sorlin, K., Wallerman, O., Karlsson, J., Yue, Q. Y., Magnusson, P. K. et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4, 40-48 (2004). (Pubitemid 38256604)
41. Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005). (Pubitemid 41131718)
42. Cha, P. C., Mushiroda, T., Takahashi, A., Saito, S., Shimomura, H., Suzuki, T. et al. High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J. Hum. Genet. 52, 856-864 (2007). (Pubitemid 47512854)
43. Lee, M. T., Chen, C. H., Chou, C. H., Lu, L. S., Chuang, H. P., Chen, Y. T. et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10, 1905-1913 (2009).
44. Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T. et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103, 2630-2635 (2004). (Pubitemid 38393017)
45. Chen, L. Y., Eriksson, N., Gwilliam, R., Bentley, D., Deloukas, P. & Wadelius, M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 106, 3673-3674 (2005). (Pubitemid 41609210)
46. Cain, D., Hutson, S. M. & Wallin, R. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J. Biol. Chem. 272, 29068-29075 (1997). (Pubitemid 27498194)
47. Loebstein, R., Vecsler, M., Kurnik, D., Austerweil, N., Gak, E., Halkin, H. et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77, 365-372 (2005). (Pubitemid 40719265)
48. Wajih, N., Sane, D. C., Hutson, S. M. & Wallin, R. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J. Biol. Chem. 279, 25276-25283 (2004). (Pubitemid 38756780)
49. Kimura, R., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K. et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120, 181-186 (2007). (Pubitemid 46754413)
50. Lin, P. J., Jin, D. Y., Tie, J. K., Presnell, S. R., Straight, D. L. & Stafford, D. W. The putative vitamin K-dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide binding site. J. Biol. Chem. 277, 28584-28591 (2002). (Pubitemid 41079286)
51. Presnell, S. R., Tripathy, A., Lentz, B. R., Jin, D. Y. & Stafford, D. W. A novel fluorescence assay to study propeptide interaction with gamma-glutamyl carboxylase. Biochemistry 40, 11723-11733 (2001). (Pubitemid 32910246)
52. Rieder, M. J., Reiner, A. P. & Rettie, A. E. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5, 2227-2234 (2007). (Pubitemid 47617875)
53. Saupe, J., Shearer, M. J. & Kohlmeier, M. Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am. J. Clin. Nutr. 58, 204-208 (1993). (Pubitemid 23227893)
54. Berkner, K. L. & Runge, K. W. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J. Thromb. Haemost. 2, 2118-2132 (2004). (Pubitemid 40185771)
55. Lal, S., Sandanaraj, E., Jada, S. R., Kong, M. C., Lee, L. H., Goh, B. C. et al. Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol. 65, 260-264 (2008). (Pubitemid 351171275)
56. Otagiri, M., Maruyama, T., Imai, T., Suenaga, A. & Imamura, Y. A comparative study of the interaction of warfarin with human alpha 1-acid glycoprotein and human albumin. J. Pharm. Pharmacol. 39, 416-420 (1987). (Pubitemid 17114396)
57. Li, T., Chang, C. Y., Jin, D. Y., Lin, P. J., Khvorova, A. & Stafford, D. W. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004). (Pubitemid 38209111)
58. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K., Pelz, H. J. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004). (Pubitemid 38209110)
59. Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005). (Pubitemid 40740552)
60. Yuan, H. Y., Chen, J. J., Lee, M. T., Wung, J. C., Chen, Y. F., Charng, M. J. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005). (Pubitemid 41430097)
61. Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827-3834 (2010).
62. Perini, J. A., Struchiner, C. J., Silva-Assuncao, E., Santana, I. S., Rangel, F., Ojopi, E. B. et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin. Pharmacol. Ther. 84, 722-728 (2008).
63. Djaffar-Jureidini, I., Chamseddine, N., Keleshian, S., Naoufal, R., Zahed, L. & Hakime, N. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genet. Test. Mol Biomarkers 15, 827-830 (2011).
64. Pathare, A., Al Khabori, M., Alkindi, S., Al Zadjali, S., Misquith, R., Khan, H. et al. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. J. Hum. Genet. 57, 665-669 (2012).
65. Suriapranata, I. M., Tjong, W. Y., Wang, T., Utama, A., Raharjo, S. B., Yuniadi, Y. et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med. Genet. 12, 80 (2011).
66. Scott, S. A., Edelmann, L., Kornreich, R. & Desnick, R. J. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82, 495-500 (2008).
67. Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
68. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
69. Cha, P. C., Mushiroda, T., Takahashi, A., Kubo, M., Minami, S., Kamatani, N. et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744 (2010).
70. Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
71. McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K. & Rettie, A. E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346 (2009).
72. Danese, E., Montagnana, M., Johnson, J. A., Rettie, A. E., Zambon, C. F., Lubitz, S. A. et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin. Pharmacol. Ther. 92, 746-756 (2012).
73. Poller, L., Wright, D. & Rowlands, M. Prospective comparative study of computer programs used for management of warfarin. J. Clin. Pathol. 46, 299-303 (1993). (Pubitemid 23138740)
74. Vadher, B. D., Patterson, D. L. & Leaning, M. S. Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. Clin. Lab. Haematol. 17, 339-345 (1995). (Pubitemid 26080275)
75. Ageno, W., Johnson, J., Nowacki, B. & Turpie, A. G. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb. Haemost. 83, 849-852 (2000). (Pubitemid 30411682)
76. Gage, B. F., Eby, C., Milligan, P. E., Banet, G. A., Duncan, J. R. & McLeod, H. L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91, 87-94 (2004). (Pubitemid 38111225)
77. Kamali, F., Khan, T. I., King, B. P., Frearson, R., Kesteven, P., Wood, P. et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75, 204-212 (2004). (Pubitemid 38314870)
78. Wei, M., Ye, F., Xie, D., Zhu, Y., Zhu, J., Tao, Y. et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb. Haemost. 107, 1083-1091 (2012).
79. Carcas, A. J., Borobia, A. M., Velasco, M., Abad-Santos, F., Diaz, M. Q., Fernandez-Capitan, C. et al. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials 13, 239 (2012).
80. Lubitz, S. A., Scott, S. A., Rothlauf, E. B., Agarwal, A., Peter, I., Doheny, D. et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8, 1018-1026 (2010).
81. Wen, M. S., Lee, M., Chen, J. J., Chuang, H. P., Lu, L. S., Chen, C. H. et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84, 83-89 (2008). (Pubitemid 351861488)
82. Choi, J. R., Kim, J. O., Kang, D. R., Yoon, S. A., Shin, J. Y., Zhang, X. et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J. Hum. Genet. 56, 290-295 (2011).
83. Biss, T. T., Avery, P. J., Brandao, L. R., Chalmers, E. A., Williams, M. D., Grainger, J. D. et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 119, 868-873 (2012).
84. Moreau, C., Bajolle, F., Siguret, V., Lasne, D., Golmard, J. L., Elie, C. et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 119, 861-867 (2012).
85. Millican, E., Jacobsen-Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E. et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110, 1511-1515 (2007). (Pubitemid 47443966)
86. Finkelman, B. S., Gage, B. F., Johnson, J. A., Brensinger, C. M. & Kimmel, S. E. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57, 612-618 (2011).
87. Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007). (Pubitemid 350179221)
88. Burmester, J. K., Berg, R. L., Yale, S. H., Rottscheit, C. M., Glurich, I. E., Schmelzer, J. R. et al. A randomized controlled trial of genotype-based coumadin initiation. Genet. Med. 13, 509-518 (2011).
89. Caraco, Y., Blotnick, S. & Muszkat, M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83, 460-470 (2008). (Pubitemid 351272635)
90. Epstein, R. S., Moyer, T. P., Aubert, R. E., O Kane, D. J., Xia, F., Verbrugge, R. R. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
91. Gong, I. Y., Tirona, R. G., Schwarz, U. I., Crown, N., Dresser, G. K., Larue, S. et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118, 3163-3171 (2011).
92. McMillin, G. A., Melis, R., Wilson, A., Strong, M. B., Wanner, N. A., Vinik, R. G. et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther. Drug. Monit. 32, 338-345 (2010).
93. Carlquist, J. F., Horne, B. D., Muhlestein, J. B., Lappe, D. L., Whiting, B. M.,Kolek,M. J. et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22, 191-197 (2006). (Pubitemid 44857780)
94. Lenzini, P. A., Grice, G. R., Milligan, P. E., Dowd, M. B., Subherwal, S., Deych, E. et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J. Thromb. Haemost. 6, 1655-1662 (2008).
95. Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L. et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93, 700-705 (2005). (Pubitemid 40485406)
96. Anderson, J. L., Horne, B. D., Stevens, S. M., Woller, S. C., Samuelson, K. M., Mansfield, J. W. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997-2005 (2012).
97. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
98. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
99. Shah, S. V. & Gage, B. F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123, 2562-2570 (2011).